PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to PDS Biotech's fourth quarter and full year of 2024 earnings conference call. At this time, all participants are currently in listen-only mode. Following the formal presentation, we'll open the call up for a question and answer session. At this time, I would now like to turn the conference over to Tom Johnson, LifeSci Advisors. Please go ahead, sir. Thank you, operator. Good morning, everyone, and welcome to PDS Biotech's 2024 results and clinical program update call. I'm joined in the call today by the following members of the company's management team. Dr. Frank Beto-Addo, Chief Executive Officer, Dr. Kirk Shepherd, Chief Medical Officer, and Lars Bostar, Chief Financial Officer. Dr. Beto-Addo will begin with an overview of the company's recent progress in its clinical development program. Mr. Bostar will review the financial results for the 2024 fiscal year. And Dr. Shepard will then join the call to help address questions from covering analysts. As a reminder, during this call, we will make forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. Any such statements should be considered in conjunction with cautionary statements in our press releases and risk factors discussed in our filings with the SEC, including our quarterly reports on Form 10-Q and annual report on Form 10-K, and these cautionary statements made during this call. We've seen no obligation to update any of these forward-looking statements or information. Now, I'd like to turn the call over to Dr. Beto Adu. Frank? Thank you, Tom, and good morning, everyone. It's our pleasure to speak with you again and to provide this brief update on our progress in advancing our cl...